AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 825780
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (external radiation and single alkylating agent chemotherapy)
Trial: 825780
Drug: Triple chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple chemotherapy (cyclophosphamide, dactinomycin, and 5-fluorouracil)
Trial: 825780
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent therapy with melphalan
Trial: 23718705
Drug: Tinidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (2 grams/day for 5 days) with chloroquine (3 days of oral weight-based dosing)
Trial: 23718705
Drug: Chloroquine and
RxNorm normalized name: chloroquine and proguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine and primaquine (standard doses)
Trial: 16700803
Drug: Efalizumab 1
RxNorm normalized name: efalizumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab 1 mg/kg SC
Trial: 14499423
Drug: THC (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (20 mg)
Trial: 14499423
Drug: THC-morphine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC-morphine (20 mg THC + 30 mg morphine)
Trial: 14499423
Drug: THC-morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC-morphine
Trial: 10682226
Drug: Flurazepam 30
RxNorm normalized name: flurazepam 30 mg oral capsule
DrugBank: Flurazepam (DB00690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurazepam 30 mg (active control)
Trial: 8104273
Drug: Citalopram 10-20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 10-20 mg daily for 3 weeks
Trial: 2868412
Drug: Thiopental (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (30 mg/kg)
Trial: 28815639
Drug: VVZ‐149 (0.25-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVZ‐149 (0.25-8 mg/kg)
Trial: 28815639
Drug: VVZ‐149 (4-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVZ‐149 (4-7 mg/kg, twice daily for 3 days)
Trial: 28815639
Drug: VVZ‐149 (0.5-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVZ‐149 (0.5-8 mg/kg)
Trial: 25154831
Drug: High-dose conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose conditioning regimens
Trial: 20633184
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication before starting NSAID therapy
Trial: 20633184
Drug: Proton-pump inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump inhibitors (PPI) therapy
Trial: 19127908
Drug: Alprazolam (medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (medication group)
Trial: 12856384
Drug: Furosemide gastroretentive
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide gastroretentive dosage form (60 mg)
Trial: 9266290
Drug: Immediate-release tablet
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tablet
Trial: 8660083
Drug: Ibuprofen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (20 mg/kg/24 hours)
Trial: 8660083
Drug: Paracetamol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (50 mg/kg/24 hours)
Trial: 8660083
Drug: Both Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both Ibuprofen and Paracetamol
Trial: 1853990
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: exclusion and treatment of symptomatic and asymptomatic infected children
Trial: 1853990
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: exclusion and treatment of symptomatic infection only
Trial: 1853990
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: exclusion and treatment of symptomatic infection, treatment of asymptomatic infection in the center
Trial: 29952159
Drug: low‐flu/val: 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low‐flu/val: 10 mg/20 mg
Trial: 27530532
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of oral levofloxacin for 3 days
Trial: 27530532
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics for 3 days
Trial: 22098272
Drug: Rifaximin 1200
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 1200 mg/d for 4 weeks
Trial: 17602085
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 600 mg daily for 26 weeks
Trial: 16133127
Drug: Imipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (mean daily dose of 248 mg, dose range 50-450 mg)
Trial: 10804906
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin re-uptake inhibitors (SSRIs)
Trial: 8679358
Drug: ketamine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 0.15 mg kg‐1
Trial: 8679358
Drug: ketamine 0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 0.30 mg kg‐1
Trial: 1651993
Drug: Cisplatin-based therapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based therapy
Trial: 1651993
Drug: Good PS
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good PS with hemoglobin level >= 11 g/dL and age > 47 years
Trial: 1651993
Drug: Hemoglobin level
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin level >= 11.0 g/dL, normal LDH, normal calcium, single metastatic site
Trial: 7038553
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg UDPG
Trial: 25644279
Drug: ombitasvir 25
RxNorm normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg for 12 or 24 weeks (subtype 1b)
Trial: 25644279
Drug: ombitasvir 25
RxNorm normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg for 12 weeks (genotype 2)
Trial: 25644279
Drug: ombitasvir 25
RxNorm normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg (genotype 2)
Trial: 24477392
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with 15 sessions at a dosage of 18 J per session over the carpal tunnel area with neutral wrist splint
Trial: 24477392
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser therapy with neutral wrist splint
Trial: 22468576
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavior therapy for psychosis (CBTp)
Trial: 18930200
Drug: Stimulation group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation group (injection of culture medium)
Trial: 18930200
Drug: SEET group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEET group (injection of embryo culture supernatant)
Trial: 10803800
Drug: tolcapone 100
RxNorm normalized name: tolcapone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone 100 mg three times daily
Trial: 1443864
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (control inhalation)
Trial: 18450803
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of vancomycin (25 mg/kg/day or 15 mg/kg/day in period 1; 30 mg/kg/day or 20 mg/kg/day in period 2)
Trial: 12501480
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of cholinesterase plus selective serotonin reuptake inhibitors (SSRIs) (citalopram HBr, 20 mg/day)
Trial: 12501480
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of cholinesterase (Donepezil, 5 mg/day)
Trial: 3202206
Drug: Propranolol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.15 mg/kg)
Trial: 2029996
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline, 0.3 ml/kg)
Trial: 31013009
Drug: H9N2-specific antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H9N2-specific antibody detection
Trial: 26154851
Drug: 30 mcg
RxNorm normalized name: Avonex 30 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mcg of EE + DRSP
Trial: 26154851
Drug: 20 mcg
RxNorm normalized name: Caverject 20 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg of EE + DRSP
Trial: 23642945
Drug: Bee venom
RxNorm normalized name: Bee venom
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bee venom acupuncture point injection (0.005% diluted in normal saline, 0.05 ml at each point, twice-weekly for three weeks)
Trial: 23642945
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (control group, twice-weekly for three weeks)
Trial: 21029347
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily for 4 weeks
Trial: 11875051
Drug: MMP1 G‐1607GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMP1 G‐1607GG allele
Trial: 11875051
Drug: Haplotypes of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haplotypes of MMP1 G‐1607GG and MMP12 Asn357Ser
Trial: 9790160
Drug: Venlafaxine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (37.5 mg daily increasing up to 225 mg daily)
Trial: 475947
Drug: Enteric-coated prednisolone
RxNorm normalized name: prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated prednisolone tablets (shellac based)
Trial: 475947
Drug: Enteric-coated prednisolone
RxNorm normalized name: prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated prednisolone tablets (cellulose acetate phthalate based)
Trial: 30915462
Drug: Tocilizumab treatment
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab treatment for 52 weeks
Trial: 25467560
Drug: Grazoprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir (100 mg) plus Elbasvir (20 mg or 50 mg) for 12 weeks without ribavirin
Trial: 25467560
Drug: Grazoprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir (100 mg) plus Elbasvir (20 mg or 50 mg) for 12 weeks with ribavirin
Trial: 25467560
Drug: Grazoprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir (100 mg) plus Elbasvir (50 mg) for 8 weeks without ribavirin
Trial: 25467560
Drug: Grazoprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir (100 mg) plus Elbasvir (50 mg) for 12 weeks
Trial: 15553108
Drug: Test tablet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test tablet (levothyroxine sodium tablets 200 microg; Eferox)
Trial: 15553108
Drug: Test tablet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test tablet vs Reference tablet
Trial: 15553108
Drug: Test tablet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test tablet vs Oral solution
Trial: 8305640
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg every 12 h)
Trial: 8305640
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg every 12 h) + Aspirin (75 mg/day)
Trial: 3329964
Drug: Cisapride 4
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisapride 4 mg or 8 mg orally three times daily for two successive three-week periods
Trial: 3329964
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally three times daily for two successive three-week periods
Trial: 30725015
Drug: Self-administered rehabilitation
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered rehabilitation program
Trial: 27717635
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 50μg
Trial: 27717635
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 100μg
Trial: 27717635
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 150μg
Trial: 27717635
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac 30mg before leaving the operating room and 15mg every 6h for 24h
Trial: 27717635
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (patient-controlled)
Trial: 27717635
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 100μg and 150μg
Trial: 27717635
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 50μg, 100μg, 150μg
Trial: 20429647
Drug: L (laser)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L (laser)
Trial: 20429647
Drug: C (no
RxNorm normalized name: SAPOSIN C (NON-GLYCOSYLATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (no treatment)
Trial: 18480686
Drug: Methylphenidate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (10 mg PO twice a day)
Trial: 16260821
Drug: Reality orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reality orientation therapy combined with donepezil
Trial: 12905915
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine mouthrinse used twice daily for 21 days
Trial: 12905915
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine mouthrinse used with routine daily brushing for 180 days
Trial: 7495392
Drug: Ibopamine (IBO)
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (IBO) 100 mg
Trial: 7495392
Drug: Captopril (CAP)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CAP) 25 mg
Trial: 2114069
Drug: Oral ftorafur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ftorafur
Trial: 18567279
Drug: Pycnogenol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (60 mg/day)
Trial: 24667161
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate 1 g/day
Trial: 24515912
Drug: Rehabilitation exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation exercise therapy combined with total glucosides form Shaoyao Gancao decoction
Trial: 24515912
Drug: Rehabilitation exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation exercise therapy only (control group)
Trial: 22926597
Drug: D-MPH-ER 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-MPH-ER 30 mg/day
Trial: 22926597
Drug: D-MPH-ER 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-MPH-ER 20 mg/day
Trial: 20479948
Drug: Amlodipine/Atorvastatin (AML/ATO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/Atorvastatin (AML/ATO) + Therapeutic Lifestyle Changes (TLC)
Trial: 20479948
Drug: Amlodipine/Atorvastatin (AML/ATO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/Atorvastatin (AML/ATO) + TLC
Trial: 12489899
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg in the first week, 200 mg in the second week)
Trial: 10516393
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) administered at 12 and 24 hours of age
Trial: 10516393
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no DEX treatment)
Trial: 7793185
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg IM 6 hourly postoperatively
Trial: 6366135
Drug: L-phenylalanine mustard
RxNorm normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-phenylalanine mustard and 5-fluorouracil (PF) with tamoxifen (T)
Trial: 6366135
Drug: L-phenylalanine mustard
RxNorm normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-phenylalanine mustard and 5-fluorouracil (PF)
Trial: 30713751
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose misoprostol + cervical Foley catheter (Group 2)
Trial: 15361383
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg triamcinolone hexacetonide (0.25 ml)
Trial: 15361383
Drug: Sterile 0.9%
RxNorm normalized name: Sodium Chloride;Vancomycin Hydrochloride;Water, Sterile 0.9%; 1 GM Intravenous Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile 0.9% saline (0.25 ml)
Trial: 9531231
Drug: Alendronate sodium
RxNorm normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate sodium (initial dose 5 mg/d, increased to 10 mg/d at 24 months)
Trial: 8232430
Drug: accelerated-dose tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: accelerated-dose tissue plasminogen activator (t-PA) with intravenous heparin
Trial: 8232430
Drug: streptokinase with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: streptokinase with subcutaneous heparin
Trial: 8232430
Drug: streptokinase with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: streptokinase with intravenous heparin
Trial: 8232430
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of both activators plus intravenous heparin
Trial: 1860196
Drug: all treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all treatment groups
Trial: 30818931
Drug: Rapid-enhanced group
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-enhanced group (40 μg at 0, 1, 2, 3 months; 60 μg at 4, 5, 6 months)
Trial: 30818931
Drug: Rapid group
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid group (40 μg at 0, 1, 2, 3 months; 20 μg at 4, 5, 6 months)
Trial: 26769956
Drug: Horizontal bed
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Horizontal bed rest combined with daily moderate intensity exercise (HAMB)
Trial: 24120953
Drug: Vaniprevir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaniprevir (600 mg twice daily) with peginterferon and ribavirin for 24 weeks (n=16)
Trial: 24120953
Drug: Vaniprevir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaniprevir (600 mg twice daily) for 24 weeks with peginterferon and ribavirin for 48 weeks (n=14)
Trial: 24120953
Drug: Vaniprevir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaniprevir (300 mg twice daily) with peginterferon and ribavirin for 48 weeks (n=15)
Trial: 24120953
Drug: Vaniprevir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaniprevir (600 mg twice daily) with peginterferon and ribavirin for 48 weeks (n=15)
Trial: 22990394
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (encouraged to increase daily steps to 10,000)
Trial: 22990394
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not asked to change daily steps)
Trial: 11524308
Drug: Acamprosate (1665‐1998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (1665‐1998 mg/day)
Trial: 3284133
Drug: Heparin/Dihydroergotamine (HDHE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin/Dihydroergotamine (HDHE)
Trial: 3284133
Drug: Heparin/Acenocoumarin (Hep/S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin/Acenocoumarin (Hep/S)
Trial: 29347996
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg methylphenidate per day (4 over-encapsulated tablets)